SCHEMBL23409664

SCHEMBL23409664

Cc1ccc(CNC(=O)Cn2cc(-c3ccnc4ccccc34)c(-c3ccccn3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 8/20 0.59
▸ MAPK14 Q16539 5/20 0.59
▸ TP53 P04637 2/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ ENPP2 Q13822 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ PKM P14618 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ YWHAG P61981 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29959820 1.00 TGFBR1 (0.59) TGFBR1MAPK14TP53CYP1A2CYP3A4
SCHEMBL28822071 0.93 TGFBR1 (0.69) TGFBR1MAPK14AURKAAURKBSMN1; SMN2
SCHEMBL28822077 0.91 TGFBR1 (0.59) TGFBR1MAPK14ENPP2LMNAMAPT
SCHEMBL23409951 0.91 TGFBR1 (0.59) TGFBR1MAPK14AURKAAURKBL3MBTL1
SCHEMBL28822090 0.91 TGFBR1 (0.62) TGFBR1MAPK14ENPP2NPSR1LMNA
SCHEMBL23409961 0.90 TGFBR1 (0.59) TGFBR1MAPK14TP53AURKAAURKB
SCHEMBL23409949 0.90 TGFBR1 (0.56) TGFBR1MAPK14TP53ENPP2SMN1; SMN2
SCHEMBL23409674 0.90 TGFBR1 (0.56) TGFBR1MAPK14AURKAAURKBNPSR1
SCHEMBL23409678 0.90 TGFBR1 (0.64) TGFBR1MAPK14
SCHEMBL29959467 0.90 TGFBR1 (0.59) TGFBR1MAPK14TP53AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Agomab Spain, S.L.U. (ES) 2025-10-30 — — US claimed
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 Agomab Spain, S.L.U. (ES) 2025-05-13 — — US claimed
CN-114787145-B Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2024-03-26 — — CN claimed
US-20230025933-A1 Benzylamide Derivatives as Inhibitors of Transforming Growth Factor-Beta Receptor I/Alk5 Agomab Spain, S.L.U. (ES) 2023-01-26 — — US claimed
CN-114787145-A Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 奥里戈生物制药有限公司 2022-07-22 — — CN claimed
WO-2021105317-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 ORIGO BIOPHARMA, S.L. (ES) 2021-06-03 — — WO claimed
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Agomab Spain, S.L.U. (ES) 2025-10-30 — — US disclosed
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 Agomab Spain, S.L.U. (ES) 2025-05-13 — — US disclosed
CN-114787145-B Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2024-03-26 — — CN disclosed
US-20230025933-A1 Benzylamide Derivatives as Inhibitors of Transforming Growth Factor-Beta Receptor I/Alk5 Agomab Spain, S.L.U. (ES) 2023-01-26 — — US disclosed
CN-114787145-A Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 奥里戈生物制药有限公司 2022-07-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 TGFBR2, TGFBR1, ACVR1 TGFBR1 2/4885MAPK14 1610/4885TP53 4225/4885
US-20230025933-A1 Benzylamide Derivatives as Inhibitors of Transforming Growth Factor-Beta Receptor I/Alk5 TGFBR2, TGFBR1, ACVR1 TGFBR1 2/4885MAPK14 1610/4885TP53 4225/4885
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 TGFBR2, TGFBR1, ACVR1 TGFBR1 2/4885MAPK14 1610/4885TP53 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback